FOLH1 and neoplasm: This review aims to evaluate the current evidence for, and current clinical applicability of, potential prognostic and predictive biomarkers for [177Lu]Lu-PSMA-617 treatment of patients with mCRPC, including imaging, clinical, and molecular biomarkers at varying stages of evaluation, including total tumor and whole-body tumor PSMA expression.